2. Search Result
Search Result
Results for "

SPECT

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

9

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128890
    DOTA-​NHS-ester
    1 Publications Verification

    		 ADC Linker Cancer
    DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .
    DOTA-​NHS-ester
  • HY-148761
    Zadavotide guraxetan
    2 Publications Verification

    PSMA I&T; PNT-2002

    		 PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    Zadavotide guraxetan
  • HY-128890B
    DOTA-​NHS-ester TFA
    1 Publications Verification

    		 ADC Linker Biochemical Assay Reagents Cancer
    DOTA-​NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-​NHS-ester can be used to label radiotracers or imaging probes for tumor detection .
    DOTA-​NHS-ester TFA
  • HY-172367
    Tc-BQ0413

    		Fluorescent Dye Cancer
    Tc-BQ0413 exhibits binds specifically to prostate-specific membrane antigen (PSMA) with good affinity. Tc-BQ0413 can be used as a single-photon emission computed tomography (SPECT) imaging agent, when labeled with technetium-99m .
    Tc-BQ0413
  • HY-146180
    FSDD0I

    		FAP Cancer
    FSDD0I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD0I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
    FSDD0I
  • HY-146181
    FSDD1I

    		FAP Cancer
    FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
    FSDD1I
  • HY-146182
    FSDD3I

    		FAP Cancer
    FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
    FSDD3I
  • HY-P11339
    c-RGD-SH

    		Integrin Cancer
    c-RGD-SH is an Integrin αvβ3 ligand. c-RGD-SH conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and 111In can be used for SPECT and NIRF imaging of tumor .
    c-RGD-SH
  • HY-163545
    Tc-Me2P

    		Drug Derivative Cancer
    Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .
    Tc-Me2P
  • HY-P9937
    Arcitumomab

    IMMU-4

    		 Transmembrane Glycoprotein Cancer
    Arcitumomab is a murine anti-carcinoembryonic antigen (CEA) monoclonal antibody Fab’ fragment. Arcitumomab can be labeled with technetium-99m and can be used for single-photon emission computed tomography (SPECT) imaging .
    Arcitumomab
  • HY-156038
    (S)-p-SCN-Bn-DOTA

    		Biochemical Assay Reagents Others
    (S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
    (S)-p-SCN-Bn-DOTA
  • HY-20167A
    H-Glu(OtBu)-OtBu hydrochloride

    		Neurokinin Receptor Cancer
    H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .
    H-Glu(OtBu)-OtBu hydrochloride
  • HY-139401
    FAPI-34
    1 Publications Verification

    		 FAP Cancer
    FAPI-34 is a fibroblast-activating protein (FAP) inhibitor with favorable pharmacokinetic and biochemical properties. (patent WO2019154886A1).
    FAPI-34
  • HY-175612
    DOTA-ALB-01

    		FAP Cancer
    DOTA-ALB-01 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-01 labeled with 68Ga or 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention. DOTA-ALB-01 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-01
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
    DOTAGA-anhydride
  • HY-175613
    DOTA-ALB-02

    		FAP Cancer
    DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-02
  • HY-P10896
    NOTA-P2-RM26

    		Bombesin Receptor Cancer
    NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
    NOTA-P2-RM26
  • HY-157977
    DOTA-GA-maleimide

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents MMP Cancer
    DOTA-GA-maleimide is a bifunctional chelator containing a DOTA macrocycle chelator, a GA linker, and a maleimide reactive group. DOTA-GA-maleimide can achieve radiolabeling of proteins by forming a stable coordination complex between the DOTA macrocycle and radioactive metal ions (such as 111In) through the specific binding of maleimide to protein thiol groups. DOTA-GA-maleimide can be used for SPECT imaging studies of MMP activity-related cancers .
    DOTA-GA-maleimide
  • HY-175744
    PSMA-MAL-5

    		PSMA Cancer
    PSMA-MAL-5 is a PSMA ligand. PSMA-MAL-5 covalently binds to Cys466 of PSMA. PSMA-MAL-5 labeled with 177Lu and 225Ac has high radiostability and tumor uptake. PSMA-MAL-5 also effectively inhibits tumor growth. PSMA-MAL-5 can be used for SPECT/CT imaging and radionuclide therapy of prostate cancer .
    PSMA-MAL-5
  • HY-P10788
    CK3 peptide

    		Complement System Cancer
    CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.
    CK3 peptide
  • HY-U00033
    Iomazenil

    		Endogenous Metabolite Neurological Disease
    Iomazenil is a benzodiazepine receptor antagonist with partial inverse agonist activity. Iomazenil can assess the binding potential of central benzodiazepine receptors in the cerebral cortex and may reflect neuronal function in viable tissue. Iomazenil use is associated with improved cognitive function in adult patients with ischemic cerebral pathology after indirect revascularization surgery. Iomazenil demonstrated restoration of benzodiazepine receptor binding potential in the affected hemisphere after surgery on brain SPECT imaging .
    Iomazenil
  • HY-P2022
    Pentetreotide

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is an indium-labelled somatostatin analog and can be uesd to nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .
    Pentetreotide
  • HY-W087187G
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
    DOTAGA-anhydride
  • HY-P5292A
    HYNIC-iPSMA TFA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA TFA
  • HY-P5292
    HYNIC-iPSMA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA
  • HY-P10744
    BQ7859

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7859
  • HY-W241345
    DOTA-bis(tert-butyl)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-bis(tert-butyl)ester is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide conjugates (RDCs). DOTA-bis(tert-butyl)ester can be conjugated with different salts to form different metal chelators, such as (HY-B1244) hydrochloride to obtain DOTA-MN2. DOTA-MN2 can be reacted with [67]Ga-citrate to obtain radiolabeling. When (67)Ga-DOTA-MN2 is incubated in phosphate buffer solution or mouse plasma for 24 hours, it does not undergo significant decomposition. In the biodistribution experiment of NFSa tumor mice, it has high tumor uptake and rapid plasma clearance, and is a good material for SPECT and PET studies.
    DOTA-bis(tert-butyl)ester
  • HY-P10792
    HER2-targeted peptide H6F

    		EGFR Cancer
    HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .
    HER2-targeted peptide H6F

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: